Literature DB >> 30509937

Is One Sample Enough? β-Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model.

Ana Motos1,2, Joseph L Kuti1, Gianluigi Li Bassi2,3,4, Antoni Torres2,3,4, David P Nicolau5,6.   

Abstract

Describing the disposition of antimicrobial agents at the site of infection is crucial to guide optimal dosing for investigational agents. For antibiotics in development for the treatment of nosocomial pneumonia, concentrations in the epithelial lining fluid (ELF) of the lung are frequently determined from a bronchoscopy at a single time point. The influence of profiles constructed from a single ELF concentration point for each subject has never been reported. This study compares the pharmacokinetics of two β-lactams, ceftolozane and piperacillin, among different ELF sampling approaches using simulated human regimens in a swine pneumonia model. Plasma and ELF concentration-time profiles were characterized in two-compartment models by the use of robustly sampled ELF concentrations and by the random selection of one or two ELF concentrations from each swine. A 5,000-subject Monte Carlo simulation was performed for each model to define the ELF penetration, as described by the ratio of the area under the concentration curve (AUC) for ELF to the AUC for free drug in plasma (AUCELF/fAUCplasma) and the probability of target attainment (PTA). Given the intersubject variability of the ELF penetrations observed, differences between the models developed using robust numbers of ELF samples versus one or two ELF samples per swine were minimal for both drugs (maximum dispersion < 20%). Using a threshold exposure target of 60% of the time that the free drug concentration remains above the MIC target, the ceftolozane and piperacillin regimens achieved PTAs of ≥90% at MICs of up to 4 and 1 μg/ml, respectively, among the different ELF sampling strategies. These models suggest that the ELF models constructed with concentrations from sparse ELF sampling time points result in exposure estimates similar to those constructed from robustly sampled ELF profiles.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  BAL sampling; Monte Carlo simulation; pneumonia

Mesh:

Substances:

Year:  2019        PMID: 30509937      PMCID: PMC6355580          DOI: 10.1128/AAC.01922-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.

Authors:  Gurudatt Chandorkar; Jennifer A Huntington; Mark H Gotfried; Keith A Rodvold; Obiamiwe Umeh
Journal:  J Antimicrob Chemother       Date:  2012-07-06       Impact factor: 5.790

2.  Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R.

Authors:  Michael N Neely; Michael G van Guilder; Walter M Yamada; Alan Schumitzky; Roger W Jelliffe
Journal:  Ther Drug Monit       Date:  2012-08       Impact factor: 3.681

3.  Penetration of vancomycin into epithelial lining fluid in healthy volunteers.

Authors:  Thomas P Lodise; George L Drusano; Jill M Butterfield; Joshua Scoville; Mark Gotfried; Keith A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

Review 4.  Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.

Authors:  Keith A Rodvold; Jomy M George; Liz Yoo
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

5.  Random sparse sampling strategy using stochastic simulation and estimation for a population pharmacokinetic study.

Authors:  Xiao-Hui Huang; Kun Wang; Ji-Han Huang; Ling Xu; Lu-Jin Li; Yu-Cheng Sheng; Qing-Shan Zheng
Journal:  Saudi Pharm J       Date:  2013-02-10       Impact factor: 4.330

6.  A novel porcine model of ventilator-associated pneumonia caused by oropharyngeal challenge with Pseudomonas aeruginosa.

Authors:  Gianluigi Li Bassi; Montserrat Rigol; Joan-Daniel Marti; Lina Saucedo; Otavio T Ranzani; Ignasi Roca; Maria Cabanas; Laura Muñoz; Valeria Giunta; Nestor Luque; Mariano Rinaudo; Mariano Esperatti; Laia Fernandez-Barat; Miquel Ferrer; Jordi Vila; Jose Ramirez; Antoni Torres
Journal:  Anesthesiology       Date:  2014-05       Impact factor: 7.892

7.  Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia.

Authors:  Marin H Kollef; Andrew Shorr; Ying P Tabak; Vikas Gupta; Larry Z Liu; R S Johannes
Journal:  Chest       Date:  2005-12       Impact factor: 9.410

8.  Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration.

Authors:  Gennaro De Pascale; Serena Fortuna; Mario Tumbarello; Salvatore Lucio Cutuli; MariaSole Vallecoccia; Teresa Spanu; Giuseppe Bello; Luca Montini; Mariano Alberto Pennisi; Pierluigi Navarra; Massimo Antonelli
Journal:  Intensive Care Med       Date:  2014-11-21       Impact factor: 17.440

9.  International study of the prevalence and outcomes of infection in intensive care units.

Authors:  Jean-Louis Vincent; Jordi Rello; John Marshall; Eliezer Silva; Antonio Anzueto; Claude D Martin; Rui Moreno; Jeffrey Lipman; Charles Gomersall; Yasser Sakr; Konrad Reinhart
Journal:  JAMA       Date:  2009-12-02       Impact factor: 56.272

10.  Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.

Authors:  Alan J Xiao; Benjamin W Miller; Jennifer A Huntington; David P Nicolau
Journal:  J Clin Pharmacol       Date:  2015-08-25       Impact factor: 3.126

View more
  4 in total

1.  Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia.

Authors:  Ana Motos; Gianluigi Li Bassi; Francesco Pagliara; Laia Fernandez-Barat; Hua Yang; Eli Aguilera Xiol; Tarek Senussi; Francesco A Idone; Chiara Travierso; Chiara Chiurazzi; Rosanel Amaro; Minlan Yang; Joaquim Bobi; Montserrat Rigol; David P Nicolau; Gerard Frigola; Roberto Cabrera; Jose Ramirez; Paolo Pelosi; Francesco Blasi; Massimo Antonelli; Antonio Artigas; Jordi Vila; Marin Kollef; Antoni Torres
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

2.  Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients.

Authors:  Yi-Chang Zhao; Yang Zou; Yi-Wen Xiao; Feng Wang; Bi-Kui Zhang; Da-Xiong Xiang; Feng Yu; Hong Luo; Indy Sandaradura; Miao Yan
Journal:  Infect Dis Ther       Date:  2021-11-06

3.  Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia.

Authors:  Luzelena Caro; David P Nicolau; Jan J De Waele; Joseph L Kuti; Kajal B Larson; Elaine Gadzicki; Brian Yu; Zhen Zeng; Adedayo Adedoyin; Elizabeth G Rhee
Journal:  J Antimicrob Chemother       Date:  2020-06-01       Impact factor: 5.790

4.  Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial.

Authors:  Adela Benítez-Cano; Sonia Luque; Luisa Sorlí; Jesús Carazo; Isabel Ramos; Nuria Campillo; Víctor Curull; Albert Sánchez-Font; Carles Vilaplana; Juan P Horcajada; Ramón Adalia; Silvia Bermejo; Enric Samsó; William Hope; Santiago Grau
Journal:  Crit Care       Date:  2020-02-17       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.